Priority Review Vouchers Explained: How an FDA Approval Becomes $180-205 Million in Cash, With $RCKT and $DNLI as Worked Examples · $XBI $IBB

01Executive Summary

On March 25, 2026, the FDA approved Denali Therapeutics’ AVLAYAH for Hunter syndrome. Two days later, on March 27, it approved Rocket Pharmaceuticals’ KRESLADI for a rare immune disorder called LAD-I. Neither approval was connected to the other — different companies, different diseases, different modalities. But both triggered the exact same reward: a Rare Pediatric Disease Priority Review Voucher (PRV), a transferable FDA asset that can be sold to any pharmaceutical company willing to pay for a faster review clock on a completely unrelated drug.

Within weeks, both companies turned that voucher into cash. Rocket signed an agreement to sell its PRV for $180 million, closing on June 10, 2026. Denali followed on June 18 with an agreement to sell its own voucher for $195 million. Combined: $375 million raised by two biotechs in the Merlintrader coverage universe, with zero new shares issued and zero new debt taken on.

These two deals were not an isolated coincidence. They were part of a broader wave: Jazz Pharmaceuticals sold a voucher for $200 million in early 2026, Fortress Biotech’s Cyprium subsidiary sold one for $205 million, and Ascendis Pharma sold one for $187.5 million — five confirmed, publicly disclosed Rare Pediatric Disease PRV sales in the space of about five months, several trade outlets noting it as the strongest pricing environment for this instrument in roughly a decade.

This piece is not primarily about tracking those five sales. It is about the mechanism underneath them: what a PRV actually is, why the program that creates it briefly stopped existing altogether in 2024-2025, how its price is really set, the fine print that quietly shrinks the “free money” narrative, how a newer and easily confused FDA voucher (the Commissioner’s National Priority Voucher) is an economically different animal, and a reusable checklist for spotting which other small and mid-cap names might be sitting on this same kind of hidden, non-dilutive option value before it ever makes a headline.

02Why This Matters Right Now: The Program That Almost Disappeared

The Rare Pediatric Disease Priority Review Voucher program has existed for years as a tool to nudge drug developers toward diseases that primarily affect children and are too rare to otherwise justify the commercial investment. But the authority behind it was never permanent. It was written into law with a sunset clause, and the version of the program that had been in place lapsed after September 30, 2024, without a clear congressional plan to extend it. For more than a year, the FDA could not award a new Rare Pediatric Disease PRV to anyone — even to a sponsor that had done everything right and earned an approval that, under the old rules, would have qualified.

That gap mattered in a very concrete way for company planning. It is common practice for small and mid-cap biotechs to flag a future PRV sale as a potential source of non-dilutive funding in their own investor materials and risk disclosures. When the underlying statute went dark, that funding lever went dark with it, for every company that had a pediatric rare disease approval on the horizon but not yet in hand.

The gap also created a subtler wrinkle that is easy to miss when scanning headlines: approval of a drug and issuance of the voucher are two separate events, and they do not have to happen at the same time. WASKYRA, a gene therapy for Wiskott-Aldrich syndrome developed by the Italian nonprofit Fondazione Telethon, was approved on December 9, 2025 — while the program was still in its lapsed state. Its voucher was not formally issued until the FDA published a Federal Register notice on February 23, 2026, weeks after reauthorization. In other words, an approval earned during the dead period had to wait for Congress to bring the program back to life before the voucher itself could actually be issued.

Congress did bring it back. The Consolidated Appropriations Act, 2026, enacted February 3, 2026, reauthorized the Rare Pediatric Disease PRV program and extended the FDA’s authority to award new vouchers through September 30, 2029. This time, lawmakers attached a condition: the Government Accountability Office must study and report to Congress on the program’s effectiveness within five years of enactment — a built-in checkpoint before the next renewal debate.

This on-again, off-again history is precisely why the mechanism deserves a plain explanation now. The market snapped back within weeks of reauthorization: ZYCUBO was approved on January 12, 2026, and its voucher sold by February 23; KRESLADI and AVLAYAH were approved in the same week in March; a cascade of further sales followed through June. The program’s fragility is not a footnote to this story — it is part of the investment picture for any biotech counting on this path.

03The Mechanism: What a PRV Actually Is

The Rare Pediatric Disease PRV program is codified at 21 U.S.C. § 360ff, part of the Federal Food, Drug, and Cosmetic Act. To earn a voucher, a sponsor must first obtain the FDA’s Rare Pediatric Disease designation for its drug or biologic — confirming the product targets a serious or life-threatening disease whose manifestations primarily affect children under 18, and that meets the FDA’s rarity criteria. If that designated product then goes on to win FDA approval through a qualifying marketing application (an NDA or BLA), the sponsor is awarded a voucher.

What the voucher actually does is narrow and specific: it entitles its holder to have one future marketing application of their choosing reviewed under priority review, which shortens the FDA’s review clock — measured from the filing date — from a standard ten months to roughly six months. Critically, that future application does not have to be for the same drug, the same disease, or even the same company that originally earned the voucher. That single feature is what turns a regulatory perk into a financial instrument: since anyone can use it on anything they choose, anyone with a pending application and a reason to want faster review has a reason to buy it.

Vouchers are fully transferable. They can be sold, and resold, an unlimited number of times, and there is no expiration date built into the certificate itself — only the statute’s own sunset date limits how much longer new vouchers can be issued in the first place. This is the biggest structural difference between a PRV and most other FDA regulatory designations, such as Orphan Drug status, Fast Track or Breakthrough Therapy designation, all of which attach permanently to a specific product and cannot be bought or sold.

There is a cost that headline coverage of these sales routinely leaves out: actually redeeming a PRV is not free. The FDA charges a separate priority review user fee to use one, recalculated every fiscal year based on the agency’s own cost difference between reviewing a priority application and a standard one. For fiscal year 2026 (October 1, 2025 through September 30, 2026), that fee is $1,962,472. A pharmaceutical company that pays $180-205 million for a voucher still has to write an additional eight-figure-adjacent check to the FDA before it can actually use the faster clock.

04The Market: Price History and the 2026 Wave

PRVs have traded as a distinct secondary market for roughly a decade. Disclosed sale prices are tracked by third-party compilations built from SEC filings, company press releases and Federal Register notices, such as Duke University’s Priority Review Voucher database and newer trackers like PRV Watch. The broad arc those trackers describe is a run from modest early prices, up toward a peak somewhere in the $300-350 million range around 2015-2022 as competition among large pharmaceutical buyers intensified, followed by a cooling into a roughly $100-175 million range through 2023-2024 as the program’s future grew uncertain heading into its lapse. (Note: these pre-2025 figures reflect the range broadly reported by aggregator sources rather than transactions independently reverified against a primary filing by Merlintrader this cycle — treat them as background context, not confirmed data points.)

What is fully confirmed, transaction by transaction, is the wave that followed reauthorization. Five Rare Pediatric Disease PRV sales have been publicly disclosed with a specific price so far in 2026:

Five disclosed sales in roughly five months, every one of them landing in a tight $180-205 million band. That is a striking degree of convergence for what is, technically, a privately negotiated market with almost no public order book and buyers who are routinely never named — a pattern worth keeping in mind as a rough anchor for what the instrument has been fetching in the current cycle, without treating it as a guarantee of where the next sale will land.

05Worked Example: Rocket Pharmaceuticals ($RCKT) and Kresladi

KRESLADI (marnetegragene autotemcel) received FDA approval on March 27, 2026, for Leukocyte Adhesion Deficiency type I (LAD-I), a severe primary immunodeficiency caused by mutations in the ITGB2 gene. Because KRESLADI carried the Rare Pediatric Disease designation, the approval automatically generated a PRV for Rocket.

Rocket moved quickly. It signed an Asset Purchase Agreement to sell the voucher on April 26, 2026 (announced publicly on April 28), to an unnamed large pharmaceutical company, and the transaction closed on June 10, 2026, for proceeds of $180 million. No new equity was issued, no warrants were attached and no debt was taken on.

The scale of the impact here is the point worth underlining: Rocket’s cash position stood at roughly $144 million as of March 31, 2026, per its 10-Q. The $180 million PRV sale pushed pro forma cash to approximately $322 million — more than doubling the company’s reported cash balance and, per company disclosure, extending its runway out to the second quarter of 2028. For a company of Rocket’s size, this single transaction was not a rounding error. It was a balance-sheet event.

06Worked Example: Denali Therapeutics ($DNLI) and Avlayah

AVLAYAH (tividenofusp alfa-eknm, also known as DNL310) received FDA approval on March 25, 2026 — two days ahead of Rocket’s Kresladi — for the neurological manifestations of Hunter syndrome (mucopolysaccharidosis type II, or MPS II) in pediatric patients without severe pre-existing cognitive impairment. Like Kresladi, the approval carried a Rare Pediatric Disease designation and automatically generated a PRV.

Denali announced an agreement to sell its voucher on June 18, 2026, for gross proceeds of $195 million, pending clearance under the Hart-Scott-Rodino antitrust review process at the time the deal was announced. On a pro forma basis, the sale would take Denali’s cash position from roughly $1.051 billion at the end of the first quarter of 2026 to more than $1.25 billion.

The contrast with Rocket is instructive, and sets up the next section: Denali is already sitting on a cash balance north of $1 billion, so $195 million is meaningful, but it is proportionally far less transformative than the same-sized transaction was for Rocket. Same instrument, same statute, same broad price range — very different weight on two different balance sheets.

07The Paradox: Same Instrument, Wildly Different Impact — and the Fine Print

Put Rocket and Denali side by side and the first lesson is about scale: identical mechanism, identical rough price tag, and yet one sale doubled a company’s cash and the other added a meaningful but secondary cushion to an already well-funded balance sheet. Before treating any PRV sale as automatically “transformative” news, the size of the number has to be measured against the size of the balance sheet it is landing on.

The clawback nobody puts in the headline

The Cyprium/Fortress Biotech transaction surfaces a detail that rarely makes it past the first paragraph of coverage: under the statute, 20% of the gross proceeds from a Rare Pediatric Disease PRV sale must be paid to the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). The sticker price on a PRV sale is not the same as the cash that actually lands on the seller’s balance sheet.

The buyer is almost always a mystery

Nearly every disclosed sale in the table above names the buyer only as an “undisclosed” or “unnamed large pharmaceutical company.” Sellers routinely decline to identify the counterparty, which leaves the market to infer motive rather than observe it directly — typically assumed to be a large-cap company with a high-value application of its own approaching a filing window, buying a few months of review-clock certainty on a drug that may have nothing to do with rare pediatric disease at all.

A voucher is not automatically cash

Holding a PRV does not guarantee a quick sale, or any sale at all. Trackers that follow voucher outcomes use a status taxonomy that includes “Sold,” “Redeemed” (used directly by the original sponsor rather than sold to a third party), “Unused,” and simply “Unknown,” where no transaction has ever been publicly disclosed. Not every Rare Pediatric Disease approval converts into a headline cash number within months — or converts at all in public view.

The fragility loop

Because the entire mechanism runs on a statute with a hard expiration date, the same kind of lapse that happened after September 30, 2024 remains a structural possibility after the new September 30, 2029 deadline. Congress built in a mandated GAO effectiveness study ahead of that date specifically because lawmakers expect to revisit the question of whether to renew the program again — which means the “free money” pipeline described in this piece is itself resting on a political decision that has already gone the wrong way once.

08Don’t Confuse It With: The Commissioner’s National Priority Voucher

A newer FDA pilot program has started generating its own steady stream of headlines: the Commissioner’s National Priority Voucher, or CNPV. It is easy to lump it in with the Rare Pediatric Disease PRV described throughout this piece, and the confusion is understandable — both promise a faster FDA review. But the two instruments are economically unrelated.

A CNPV is awarded at the FDA’s own discretion to applications the agency identifies as aligned with certain national health priorities, rather than being triggered automatically by a statutory criterion like a rare pediatric disease approval. Its speed benefit is even more dramatic than a standard PRV — potentially compressing review to somewhere around one to two months rather than the roughly six-month priority review timeline discussed above. But a CNPV cannot be sold or transferred to another company under any circumstances, and it must be redeemed within two years of being awarded or it is simply lost.

That single restriction changes everything about how to think about it. A Rare Pediatric Disease PRV is both a speed benefit and a saleable financial asset — which is why it shows up in 8-K filings with dollar signs attached. A CNPV is only a speed benefit; it can never appear in a press release as a $180 million transaction, no matter how high-profile the drug attached to it.

It is also worth noting that a priority voucher of either kind buys review speed, not a guaranteed outcome. Disc Medicine’s bitopertin still received a Complete Response Letter — an FDA rejection — in February 2026 despite holding a CNPV, a useful reminder that neither voucher program overrides the FDA’s substantive review of the underlying data.

09A Reusable Triage Checklist: Spotting Hidden PRV Optionality

The mechanism above is only useful if it can be applied to the next company, not just the two used as worked examples here. The following is a due-diligence starting point — a set of questions to research independently through primary sources, not a signal to act on by itself.

1. Does the company already hold an FDA Rare Pediatric Disease designation for its lead program? This is a matter of public record and is normally disclosed in company press releases and 10-K/10-Q risk factor sections.
2. Is there an active marketing application (NDA or BLA) filed, or a clearly telegraphed filing timeline, with a PDUFA date on the calendar? A designation alone does not generate a voucher — approval does.
3. Has management explicitly flagged PRV monetization as a funding lever in investor materials, earnings calls or risk disclosures? Many companies planning around this do say so directly.
4. Does management have any track record of moving quickly on non-core asset sales? Cyprium struck its PRV sale within about six weeks of Zycubo’s approval — a useful reference point for how fast this can move once a company decides to sell.
5. How large is the number relative to the company’s cash position? As Section 07 shows, the same $180-205 million range can double a small cap’s cash balance or barely move the needle for a company already sitting on a billion dollars — the size of the company determines whether this is a transformative event or a rounding error.

10Mapping the Neighborhood: RPD PRV Activity in 2025-2026

Beyond the five confirmed sales already detailed in Section 04, a further group of Rare Pediatric Disease vouchers has been issued or reported since the program’s reauthorization, though not all of them have a publicly confirmed sale price. The table below separates what is independently confirmed from what is not.

11Risks and What Still Has to Be Demonstrated

• Legislative risk is not hypothetical: the program has already lapsed once, for over a year, and carries a new hard sunset date of September 30, 2029, with a mandated GAO study set up ahead of the next renewal decision.
• The buyer side of the market is opaque: with almost every counterparty undisclosed and no public order book, there is no reliable way to know in advance what a specific future voucher will fetch.
• Monetization is not guaranteed or automatic: holding a Rare Pediatric Disease designation, or even an approval, does not guarantee a fast sale, a favorable price, or any sale at all — some issued vouchers remain unsold or undisclosed for extended periods.
• The statutory clawback reduces net proceeds: 20% of gross proceeds must be paid to the Eunice Kennedy Shriver NICHD, meaning the headline sale price overstates the cash that actually reaches the seller.
• A PRV sale validates a balance sheet event, not the underlying business: a company can hold a very valuable, purely non-dilutive check and still face unresolved pipeline, competitive or commercial execution risk on everything else it is working on.
• The redemption fee is a real cost for the eventual user: at $1,962,472 for fiscal year 2026, it is not large relative to a $180-205 million purchase price, but it is not zero either.

12Bottom Line

The Rare Pediatric Disease Priority Review Voucher program converts a narrow, specific regulatory outcome — approval of a drug for a serious pediatric disease that is both rare and life-threatening — into a transferable financial asset. In 2026, that asset has traded, across five confirmed transactions, in a tight $180-205 million band. The mechanism is genuinely non-dilutive: no new shares, no new debt. But it is layered with a statutory clawback that quietly reduces net proceeds, a redemption fee the eventual buyer has to pay separately, counterparties who are almost never named, and — above everything else — a legislative expiration clock that has already gone dark once and is scheduled to expire again in 2029 unless Congress acts a second time.

For a reader following small and mid-cap biotech, the two-part skill this piece is meant to leave behind is straightforward: recognize when a company might be sitting on this kind of hidden, non-dilutive option value before it is ever announced, using the checklist in Section 09; and when a PRV sale does make headlines, read past the sticker price to the fine print in Section 07 before deciding how much it actually changes the picture.